Clofarabine, Cyclophosphamide and Etoposide for Minimal Residual Disease Positive Acute Leukemia
Status:
Withdrawn
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
Study Design:
This is a two-stage Phase II trial investigating the efficacy of Clofarabine,
Cyclophosphamide and Etoposide in acute leukemia patients with detectable minimal residual
disease (MRD) prior to allo-HCT. The primary objective is to determine the impact of the
study treatment in eliminating the presence of minimal residual disease without causing a
significant delay of allo-HCT due to treatment related toxicity. The intent of this study is
to allow patients to proceed to transplant (independent of this study) within 42 days of Day
1 of Clofarabine based therapy.